Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

This phase 3 multicenter, randomized, double-blind, placebo-controlled 2-year trial compared the efficacy and safety of intravenous belimumab with those of placebo, plus standard therapy, in patients with active lupus nephritis. More patients who received belimumab had a primary efficacy renal respo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-09, Vol.383 (12), p.1117-1128
Hauptverfasser:	Furie, Richard, Rovin, Brad H, Houssiau, Frédéric, Malvar, Ana, Teng, Y.K. Onno, Contreras, Gabriel, Amoura, Zahir, Yu, Xueqing, Mok, Chi-Chiu, Santiago, Mittermayer B, Saxena, Amit, Green, Yulia, Ji, Beulah, Kleoudis, Christi, Burriss, Susan W, Barnett, Carly, Roth, David A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Azathioprine Azathioprine - therapeutic use Biopsy Body weight Clinical trials Creatinine Creatinine - urine Cyclophosphamide Cyclophosphamide - therapeutic use Double-Blind Method Double-blind studies Drug Therapy, Combination Enzyme Inhibitors - therapeutic use Epidermal growth factor receptors Failure FDA approval Female Glomerular Filtration Rate Humans Immunosuppressive agents Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Infusions, Intravenous Intention to Treat Analysis Intravenous administration Kidneys Lupus Lupus nephritis Lupus Nephritis - drug therapy Lupus Nephritis - mortality Male Monoclonal antibodies Mycophenolate mofetil Mycophenolic acid Mycophenolic Acid - therapeutic use Nephritis Proteins Remission Induction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This phase 3 multicenter, randomized, double-blind, placebo-controlled 2-year trial compared the efficacy and safety of intravenous belimumab with those of placebo, plus standard therapy, in patients with active lupus nephritis. More patients who received belimumab had a primary efficacy renal response than those who received placebo.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2001180